The CLARINET study: Assessing the effect of lanreotide autogel on tumor progression-free survival in patients with nonfunctioning gastroenteropancreatic neuroendocrine tumors.

被引：0
|
作者：
Delavault, Patrick
Caplin, Martyn E.
Liyange, Nilani
Blumberg, Joelle
机构：
[1] Ipsen Innovat, Paris, France
[2] Royal Free Hosp, European ENETS Ctr Excellence, Neuroendocrine Tumour Unit, London NW3 2QG, England
[3] Ipsen Innovat, Les Ulis, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS4153
引用
收藏
页数：1
相关论文
共 50 条
  • [1] The CLARINET Study - Assessing the Effect of Lanreotide Autogel on Tumor Progression-Free Survival in Patients with Non-Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
    Joelle, Blumberg
    Nilani, Liyanage
    Martyn, Caplin
    PANCREAS, 2012, 41 (02) : 343 - 343
  • [2] Lanreotide Autogel Significantly Improves Tumor Progression-Free Survival in Patients with Non-Functioning Gastroenteropancreatic Neuroendocrine Tumors: Results of the CLARINET Study
    Caplin, Martyn
    Phan, Alexandria
    Liyanage, Nilani
    Gomez-Panzani, Edda
    Blumberg, Joelle
    PANCREAS, 2014, 43 (03) : 495 - 495
  • [3] Establishing the Quantitative Relationship Between Lanreotide Autogel®, Chromogranin A, and Progression-Free Survival in Patients with Nonfunctioning Gastroenteropancreatic Neuroendocrine Tumors
    Núria Buil-Bruna
    Marion Dehez
    Amandine Manon
    Thi Xuan Quyen Nguyen
    Iñaki F. Trocóniz
    The AAPS Journal, 2016, 18 : 703 - 712
  • [4] Relationship Between Lanreotide Autogel, Chromogranin A and Progression-Free Survival in Patients With Gastroenteropancreatic Neuroendocrine Tumors
    Buil-Bruna, Nuia
    Dehez, Marion
    Manon, Amandine
    Thi Xuan Quyen Nguyen
    Troconiz, Inaki F.
    PANCREAS, 2016, 45 (03) : 472 - 473
  • [5] Relationship between lanreotide autogel, chromogranin A and progression-free survival in patients with gastroenteropancreatic neuroendocrine tumours
    Buil-Bruna, N.
    Dehez, M.
    Manon, A.
    Xuan, Q. N. Thi
    Troconiz, I.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S448 - S448
  • [6] Establishing the Quantitative Relationship Between Lanreotide AutogelA®, Chromogranin A, and Progression-Free Survival in Patients with Nonfunctioning Gastroenteropancreatic Neuroendocrine Tumors
    Buil-Bruna, Nuria
    Dehez, Marion
    Manon, Amandine
    Thi Xuan Quyen Nguyen
    Troconiz, Inaki F.
    AAPS JOURNAL, 2016, 18 (03): : 703 - 712
  • [7] Final Progression-Free Survival Analyses for Lanreotide Autogel/Depot 120 mg in Metastatic Enteropancreatic Neuroendocrine Tumors: The CLARINET Extension Study
    Wolin, Edward M.
    Pavel, Marianne E.
    Cwikla, Jaroslaw B.
    Phan, Alexandria T.
    Raderer, Markus
    Sedlackova, Eva
    Cadiot, Guillaume
    Capdevila, Jaume
    Wall, Lucy
    Rindi, Guido
    Lombard-Bohas, Catherine
    Liyanage, Nilani
    Thanh, Xuan-Mai Truong
    Ruszniewski, Philippe B.
    Caplin, Martyn E.
    Investigators, Clarinet
    PANCREAS, 2018, 47 (03) : 358 - 359
  • [8] Multivariate Analysis of Progression-Free Survival in the CLARINET Study of Lanreotide Autogel/Depot vs Placebo Identifies Prognostic Factors in Neuroendocrine Tumors
    Wolin, Edward M.
    Caplin, Martyn E.
    Pavel, Marianne E.
    Cwikla, Jaroslaw B.
    Phan, Alexandria T.
    Raderer, Markus
    Sedlackova, Eva
    Cadiot, Guillaume
    Capdevila, Jaume
    Wall, Lucy
    Rindi, Guido
    Langley, Alison
    Gomez-Panzani, Edda
    Ruszniewski, Philippe B.
    PANCREAS, 2016, 45 (03) : 486 - 486
  • [9] Prognostic factors for progression-free survival (PFS) in CLARINET study of lanreotide depot/autogel (LAN) vs placebo (PBO) in neuroendocrine tumors (NETs).
    Wolin, Edward M.
    Caplin, Martyn E.
    Pavel, Marianne E.
    Cwikla, Jaroslaw B.
    Phan, Alexandria T.
    Raderer, Markus
    Sedlackova, Eva
    Cadiot, Guillaume
    Capdevila, Jaume
    Wall, Lucy
    Rindi, Guido
    Langley, Alison
    Gomez-Panzani, Edda
    Ruszniewski, Philippe B.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [10] Tumor Response in the CLARINET Study of Lanreotide Depot/Autogel vs Placebo in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (03) : 11 - 12
12345